Search

for
Search:

Glossary Dasatinib

medication used to treat certain types of leukemia

Dasatinib is a medication primarily used to treat certain types of leukemia, a cancer of the blood cells. It works by inhibiting specific proteins that promote the growth of cancer cells, thereby slowing or stopping their proliferation. For professionals, it's known as a tyrosine kinase inhibitor and is effective against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with the Philadelphia chromosome.

Related Terms

Research

5 / 124 results

Adverse Cutaneous Reactions to the New Second-Generation Tyrosine Kinase Inhibitors (Dasatinib, Nilotinib) in Chronic Myeloid Leukemia

research Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia

25 citations , November 2013 in “Journal of the American Academy of Dermatology”

This study observed that 71% of chronic myeloid leukemia patients treated with second-generation tyrosine kinase inhibitors experienced adverse cutaneous reactions, which were generally less severe than those caused by imatinib.

research Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia

9 citations , May 2013 in “JAMA Dermatology”

This report details a case of extensive leukotrichia induced by dasatinib in a patient with refractory chronic myelogenous leukemia.

research Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects

508 citations , June 2009 in “Current drug metabolism”

This review details the skin and hematological toxicities of tyrosine kinase inhibitors like erlotinib, gefitinib, and imatinib, and highlights ongoing concerns about cardiac toxicity, reporting no new clinical findings.

research Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

32 citations , September 2015 in “Dermatology”

This study describes a newly recognized skin reaction associated with dasatinib, nilotinib, and ponatinib, marked by a lichenoid exanthem with severe pruritus that may necessitate discontinuation of therapy.